Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBM4003 + Toripalimab in Advanced HCC and Other Solid Tumors
NCT05149027Phase 1Unknown
- Sponsor
- Harbour BioMed
- Start
- Dec 2021
- Primary completion
- May 2024
- Modality
- Antibody Conjugates, Nanobodies (VHH), Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of porustobart in hepatocellular carcinoma (HCC) and solid tumor, sponsored by Harbour BioMed. Primary endpoints: Dose-Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 2 more. Status: unknown.
02
Drugs
porustobart
03
Conditions
hepatocellular carcinoma (HCC)solid tumor
Beyond the preview
Go deeper on NCT05149027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05149027.